TRx0014 in Patients With Mild or Moderate Alzheimer’s Disease (NCT00515333) (2008)

Government Record · TauRx Therapeutics Ltd (sponsor); ClinicalTrials.gov record · February 20, 2008

TauRx Therapeutics Ltd (sponsor), 2008-02-20: Registry record for the phase 2 Rember trial: 323 participants, four arms (placebo and 30, 60 or 100 mg three times daily), 24-week primary ADAS-cog endpoint; completed, no results posted.

Treatment group: 100 milligrams; t.i.d.

TauRx Therapeutics Ltd (sponsor), 2008-02-20: Registry record for the phase 2 Rember trial: 323 participants, four arms (placebo and 30, 60 or 100 mg three times daily), 24-week primary ADAS-cog endpoint; completed, no results posted. Record fields from ClinicalTrials.gov API v2 (armGroups, enrollmentInfo=323 actual, phases=PHASE2, start 2004-08, completion 2007-12, hasResults=false). Registered, no results posted. Note the discrepancy between the registry's nominal doses (30/60/100 mg t.i.d.) and the 69/138/228 mg/day actually delivered as reported in the 2015 paper (MTC-031) – the task brief's '60/100/150 mg tid' arms do not match either source; the registry is authoritative for the nominal doses. hosting=LINK because the ClinicalTrials.gov study record is HTML-only (no PDF); copyright remains US Federal Public Domain. The record text was read from https://clinicaltrials.gov/api/v2/studies/NCT00515333 and the study page is JavaScript-rendered. Also filed as MTC-073 (claims C11, F1).